Alphabet's Isomorphic Labs Raises $600M for AI-Driven Drug Discovery

Isomorphic Labs, an AI-driven drug discovery company and subsidiary of Alphabet, has secured $600 million in its first external funding round. The investment was led by Thrive Capital, with participation from GV (formerly Google Ventures) and additional backing from Alphabet.
Founded in 2021 and based in London, Isomorphic Labs aims to leverage artificial intelligence to revolutionize drug design and development. The company utilizes AI models, including DeepMind's AlphaFold, to predict protein structures, thereby accelerating the drug discovery process.